7H-pyrido[4,3-c]carbazole | 205-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 7H-pyrido[4,3-c]carbazole
• 英文别名: 7H-Pyrido[4,3-c]carbazol；7-H-Pyrido<4.3-c>carbazol；7H-Pyrido(4,3-c)carbazole；7H-pyrido[4,3-c]carbazole
• CAS: 205-29-8
• 化学式: C₁₅H₁₀N₂
• 分子量: 218.258
• InChiKey: WNKWCVDUFJGGSD-UHFFFAOYSA-N

物化性质

• 沸点：
  488.6±18.0 °C(Predicted)
• 密度：
  1.336±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉-7-醇 在 甲醇 作用下， 生成 7H-pyrido[4,3-c]carbazole
  参考文献：
  名称：

  Manske; Kulka, Canadian Journal of Research, Section B: Chemical Sciences, 1949, vol. 27, p. 291,295

  摘要：

  DOI：

文献信息

• Tetracyclic lactam derivatives and uses thereof
  申请人：Jagtap Prakash

  公开号：US20050261288A1

  公开（公告）日：2005-11-24

  The present invention relates to Tetracyclic Lactam Derivatives, compositions comprising an effective amount of a Tetracyclic Lactam Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, reoxygenation injury resulting from organ transplantation, Parkinson's disease, or cancer, comprising administering to an animal in need thereof an effective amount of a Tetracyclic Lactam Derivative.

  本发明涉及四环内酰胺衍生物，包括有效量的四环内酰胺衍生物的组合物，以及治疗或预防炎症性疾病、再灌注损伤、缺血症状、肾衰竭、糖尿病、糖尿病并发症、血管疾病、器官移植引起的再氧化损伤、帕金森病或癌症的方法，包括向需要的动物施用有效量的四环内酰胺衍生物。
• Tetracyclic benzamide derivatives and methods of use thereof
  申请人：Inotek Pharmaceuticals Corporation

  公开号：US20040229895A1

  公开（公告）日：2004-11-18

  The invention relates to Tetracyclic Benzamide Derivatives; compositions comprising a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer, comprising administering to a subject in need thereof an effective amount of a Tetracyclic Benzamide Derivative.

  该发明涉及四环苯甲酰胺衍生物；包含四环苯甲酰胺衍生物的组合物；以及用于治疗或预防炎症性疾病、再灌注疾病、缺血症状、肾功能衰竭、糖尿病、糖尿病并发症、血管疾病或癌症的方法，包括向需要的受试者施用有效剂量的四环苯甲酰胺衍生物。
• [EN] METHODS FOR THE SYNTHESIS OF HETEROATOM CONTAINING POLYCYCLIC AROMATIC HYDROCARBONS<br/>[FR] PROCÉDÉS DE SYNTHÈSE D'HYDROCARBURES AROMATIQUES POLYCYCLIQUES CONTENANT DES HÉTÉROATOMES
  申请人：UNIV CALIFORNIA

  公开号：WO2020041369A1

  公开（公告）日：2020-02-27

  Methods for the synthesis of polycyclic aromatic hydrocarbons and synthesis platforms for performing such syntheses are provided. Methods and platforms are provided that allow for the synthesis of aza-polycyclic aromatic hydrocarbons by an expedient ring assembly. Methods and platforms allow for a modular approach to synthesis that provide multiple new C-C bonds in sequential pericyclic reactions, thus giving access to compounds with multiple axes of substitution.

  提供了合成多环芳烃的方法和执行这些合成的合成平台。提供了允许通过迅速的环组装合成氮杂多环芳烃的方法和平台。提供了模块化合成方法和平台，通过连续的周环反应提供多个新的C-C键，从而获得具有多个取代轴的化合物。
• Gene expression system based on chimeric receptors
  申请人：——

  公开号：US20040102367A1

  公开（公告）日：2004-05-27

  The invention provides a system for modulating the expression of a target gene in a subject wherein a defined response element for a DNA binding domain modulates expression of said target gene. The invention system comprises two chimeric proteins, each containing the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily, one of which is non-endogenous to the subject. In addition, the first chimeric protein contains a DNA binding domain to which the target gene is responsive and the second chimeric protein contains a transcription modulating domain, such as a transcription activator or a transcription repressor. In one embodiment of the invention, two invention systems form a dimer having the properties of a native heterodimer or homodimer. In another embodiment, only the first chimeric protein contains a DNA binding domain and only the second chimeric protein contains a transcription activating domain. The functional entity formed by association of the first and second chimeric proteins can be designed to transactivate transcription by complexing with a DNA binding recognition site that does not have the 2-half site format common to response elements for members of the steroid/thyroid hormone nuclear receptor superfamily. Thus, certain of the invention systems cannot functionally interact with endogenous proteins in the way that wild type receptors do. The invention further provides nucleic acid sequences encoding the invention chimeric proteins, cells containing such nucleic acid sequences, and methods for using the invention chimeric proteins to modulate expression of one or more non-endogenous genes in a subject organism.

  本发明提供了一种调节受试者体内靶基因表达的系统，其中 DNA 结合结构域的确定反应元件可调节所述靶基因的表达。本发明系统包括两个嵌合蛋白，每个嵌合蛋白都含有类固醇/甲状腺激素核受体超家族成员的二聚化结构域，其中一个是受试者的非内源性蛋白。此外，第一个嵌合蛋白含有 DNA 结合结构域，靶基因对其有反应；第二个嵌合蛋白含有转录调节结构域，如转录激活剂或转录抑制剂。在本发明的一个实施方案中，两个发明系统形成的二聚体具有原生异源二聚体或同源二聚体的特性。在另一个实施方案中，只有第一个嵌合蛋白含有 DNA 结合结构域，只有第二个嵌合蛋白含有转录激活结构域。第一种和第二种嵌合蛋白结合形成的功能实体可通过与 DNA 结合识别位点复合来激活转录，该识别位点不具有类固醇/甲状腺激素核受体超家族成员的反应元件所共有的 2-半位点格式。因此，本发明的某些系统不能像野生型受体那样与内源蛋白发生功能性相互作用。本发明进一步提供了编码本发明嵌合蛋白的核酸序列、含有此类核酸序列的细胞，以及使用本发明嵌合蛋白调节受试生物体中一个或多个非内源基因表达的方法。
• GENE EXPRESSION SYSTEM BASED ON CHIMERIC RECEPTORS
  申请人：THE SALK INSTITUTE FOR BIOLOGICAL STUDIES

  公开号：EP1259537A1

  公开（公告）日：2002-11-27